396 results on '"ATOPIC dermatitis"'
Search Results
2. Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
- Author
-
REGUIAI, Ziad, BECHEREL, Pierre André, PERROT, Jean Luc, FOUGEROUSSE, Anne Claire, BEGON, Edouard, POREAUX, Claire, BOULARD, Claire, CHABY, Guillaume, FITE, Charlotte, ZARAA, Inès, LONS-DANIC, Dominique, LIEGEON, Anne-Laure, PARIER, Josiane, QUILES-TSIMARATOS, Nathalie, DAVID, Laurene, and MACCARI, François
- Subjects
- *
ATOPIC dermatitis , *MEDICAL registries , *SKIN diseases , *BARICITINIB , *QUALITY of life - Abstract
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patientreported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus.
- Author
-
PEREYRA-RODRIGUEZ, Jose J., BALDRICH, Esther S., RUIZ-VILLAVERDE, Ricardo, TORRES, Eulalia B., DOBAO, Pablo DE LA C., NART, Ignasi F., MENÉNDEZ, Ángeles F., MARTIN-SANTIAGO, Ana, MIQUEL, Javier M., SILVESTRE, Juan F., and ARMARIO-HITA, Jose C.
- Subjects
- *
ATOPIC dermatitis , *DELPHI method , *LITERATURE reviews , *PATIENT satisfaction , *IMMUNOGLOBULIN E - Abstract
Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic approach, method to assess severity, and patient follow-up for this condition. An expert consensus study was conducted to provide recommendations on the management of patients with moderate-to-severe atopic dermatitis. The study used Delphi-like methodology based on a literature review, a summary of the scientific evidence, and a 2-round survey. The agreement of 60 panellists on 21 statements was evaluated. Consensus was predefined as ≥80% agreement of all respondents. In the first round 6 statements reached consensus. Unanimous consensus was achieved regarding therapeutic goals and patient satisfaction (maintained in the long term and periodic goals reassessment recommended every 3–6 months). In the second round, half of the statements reached consensus, all related to patient follow-up, treatment goals, and atopic comorbidities. The statements that did not reach consensus were related to diagnosis (biomarkers, allergy, and food testing) and starting patients on conventional systemic treatment rather than advanced treatment. The study assessed expert opinion regarding a variety of topics related to the clinical approach to patients with moderate-to-severe atopic dermatitis, in order to provide guidance on the diagnosis and management of patients with atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis.
- Author
-
PAVLENKO, Darya, SEVEN, Zeynep Todurga, BYSTROM, Lauren, MARKAN, Anika, VERPILE, Rebecca, ISHIDA, Hirotake, and AKIYAMA, Tasuku
- Subjects
- *
ITCHING , *ATOPIC dermatitis , *LABORATORY mice , *ANIMAL disease models , *DORSAL root ganglia , *NEUTROPHILS - Abstract
Crisaborole, a phosphodiesterase 4 (PDE4) inhibitor, has been approved for the treatment of mild to moderate atopic dermatitis. Atopic dermatitis is often associated with increased pain. Using a mouse model, this study investigated whether crisaborole suppresses pain associated with atopic dermatitis and the potential mechanisms underlying it. The mouse model for atopic dermatitis was developed by repeatedly applying MC903. MC903-treated mice had increased spontaneous scratching (itch-related behaviour) and wiping behaviour (pain-related behaviour). Crisaborole was topically applied to the cheek skin of MC903-treated mice, and it reduced both itch- and pain-related behaviours in these mice. Immunofluorescence staining revealed that crisaborole reduced neutrophil infiltration and interaction of neutrophils with sensory neurones. Intradermal injection of S100A8/A9, proinflammatory neutrophil mediator, enhanced not only itch-related behaviours evoked by histamine or chloroquine, but also pain-related behaviours evoked by capsaicin. Calcium imaging of mouse dorsal root ganglion neurones revealed that pretreatment with S100A8/A9 significantly increased calcium responses to histamine and capsaicin, and the proportion of chloroquine-sensitive neurones. These findings suggest that the PDE4 inhibitor reduces itch and pain, in part by inhibiting infiltration of S100A8/A9-containing neutrophils in a mouse model of MC903-induced atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Atopic Dermatitis in the Elderly Population.
- Author
-
MAURELLI, Martina, CHIRICOZZI, Andrea, PERIS, Ketty, GISONDI, Paolo, and GIROLOMONI, Giampiero
- Subjects
- *
ATOPIC dermatitis , *OLDER people , *ITCHING , *DISEASE relapse , *JUVENILE diseases , *CHRONIC diseases - Abstract
Atopic dermatitis is a common inflammatory disease with a chronic and relapsing course. Although considered a childhood disease, it is now evident that atopic dermatitis is also common in adulthood and in the elderly population. Atopic dermatitis typically manifests with bilateral and symmetrical eczematous lesions on the face, trunk and skin folds. Itch is invariably present and may be very severe, markedly affecting daily life and sleep. In older adults, atopic dermatitis may have a high level of impact on quality of life, frequently burdening an already complex comorbid situation. The full assessment of disease burden (localizations, itch severity, sleep alterations, impact on quality of life, disease history, comorbidities) is crucial to identify the most appropriate treatment. In many cases, moderate-to-severe atopic dermatitis in the elderly population can be successfully and safely treated with biological agents inhibiting the interleukin-4/-13 pathway, whereas the use of Janus kinase inhibitors may pose concerns about the safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Nocturnal Scratching and Quality of Sleep in Children with Atopic Dermatitis.
- Author
-
SUGIYAMA, Akiko, MURAKAMI, Yoko, OKAMOTO, Kazuaki, NAKANO, Hiroshi, WAKATSUKI, Masatoshi, KAWANO, Toshiaki, AKAMINE, Yuko, IWATA, Mihoko, MOTOMURA, Chikako, KOJIMA, Kaoru, ODA, Makiko, HONJO, Satoshi, ODAJIMA, Hiroshi, NAKAHARA, Takeshi, FURUE, Masutaka, and IKOMA, Akihiko
- Subjects
- *
SLEEP quality , *ATOPIC dermatitis , *SLEEP stages , *SLEEP disorders , *ITCHING - Abstract
Itching due to atopic dermatitis causes sleep disorders in children, but its pathology is unknown. The aim of this study is to investigate nocturnal scratching as an indirect index of itching during sleep and its relationship with depth of sleep in children with atopic dermatitis. Nocturnal scratching was measured in a total of 20 children with atopic dermatitis, using a smartwatch installed with the application Itch Tracker. Depth of sleep was analysed using polysomnography. The severity of atopic dermatitis was scored using Eczema Area and Severity Index (EASI) and Patient-Oriented Eczema Measure (POEM). The number and time of nocturnal scratching measured by Itch Tracker had a significantly positive correlation with EASI scores, whereas POEM scores were not correlated with EASI scores. Mean sleep efficiency was 90.0% and scratching episodes (n=67) started mainly during the awake stage or light sleep stages. In the scratching episodes that started during sleep stages (n=34), the sleep stage changed to a lighter one or to the awake stage in 35.5% of episodes. Itch Tracker is applicable to measure nocturnal scratching in children. Nocturnal scratching can deteriorate quality of sleep by changing the sleep stage to a lighter one or to the awake stage. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Monitoring Sleep and Scratch Improves Quality of Life in Patients with Atopic Dermatitis.
- Author
-
YASUDA, Ken-ichi, ISHIUJI, Yozo, EBATA, Toshiya, KOGURE, Takamasa, KONDO, Eitaro, OTA, Arihito, ITO, Toshihiro, ENDOH, Koki, and ASAHINA, Akihiko
- Subjects
- *
ATOPIC dermatitis , *SLEEP interruptions , *QUALITY of life , *MOBILE apps , *SLEEP , *POLYSOMNOGRAPHY - Abstract
Atopic dermatitis itch may cause sleep disturbance and impair quality of life. For patients finding topical therapy difficult to continue, it is important to control itch and reduce scratching. This study developed algorithms to measure nocturnal sleep and scratch, using an actigraph device worn on the back of the hand, and assessed smartphone application feedback to improve adherence with therapy. In the first trial, actigraph measurements in 5 participants who wore the device were highly correlated with measurements by a sleep-monitoring device beneath the mattress. Total actigraph-measured scratching duration for each hour of sleep was highly correlated with measurements by a person rating infrared video-recording of the sleepers. In the second trial, 40 patients with atopic dermatitis were randomly allocated into an intervention group that used the actigraph and smartphone application, and a control group that did not. Both groups were instructed to use the same moisturizer. Dermatology Life Quality Index scores decreased significantly from baseline and were lower than those in the control group at week 8. It is suggested that the device and associated smartphone application reinforced therapy adherence, moisturizer use, and contributed to improved quality of life in patients with atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Effects of Magnoliae Flos on Atopic Dermatitis-Like Inflammation Evaluated via Extracellular Signal-regulated Kinase or Signal Transducers and Activators of Transcription 1/3 Signalling Pathways.
- Author
-
Tae-Young GIL, Bo-Ram JIN, Yea-Jin PARK, Hye-Min KIM, and Hyo-Jin AN
- Subjects
- *
CELLULAR signal transduction , *ATOPIC dermatitis , *INFLAMMATION , *TRANSDUCERS , *ORGAN playing - Abstract
Atopic dermatitis is a chronic inflammatory skin disease. Skin is the largest organ and plays a pivotal role in protecting the body. Not only does the skin act as a physical barrier against the external environment, but it also has its own immune system. Atopic dermatitis is caused by prolonged excessive inflammatory responses that worsen under imbalanced cutaneous immune system skin conditions. Although the prevalence and burden of atopic dermatitis is increasing, the standard therapeutic agents remain unclear due to the complicated pathophysiology of the condition. The objective of this study is to examine the use of Magnoliae flos, the dried flower bud of Magnolia biondii or related plants. The effects and underlying mechanism of action of aqueous extract of the buds of Magnoliae flos (MF) were evaluated. Immortalized human keratinocytes (HaCaT) stimulated with tumour necrosis factor-α and interferon-γ mixture and NC/Nga mice stimulated with 2,4-dinitrochlorobenzene were used as atopic dermatitis models, in vitro and in vivo, respectively. The effects of MF were determined by measuring the suppression of pro-inflammatory signalling pathways, such as extracellular signal-regulated kinase or signal transducers and activators of transcription 1/3 and restoring skin barrier molecules. In conclusion, MF is a potential therapeutic alternative for the treatment of atopic dermatitis through repressing inflammatory pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Prevalence of Isotretinoin Therapy in Adolescents and Young Adults With and Without Atopic Dermatitis: A Nationwide Prescription based Population Study.
- Author
-
MOHN, Cathrine H., BLIX, Hege S., BRÆND, Anja Maria, NAFSTAD, Per, and HALVORSEN, Jon Anders
- Subjects
- *
ATOPIC dermatitis , *YOUNG adults , *ISOTRETINOIN , *TEENAGERS , *MEDICAL prescriptions - Abstract
Although isotretinoin has anti-inflammatory and immunomodulatory properties, it can exacerbate atopic dermatitis. National estimates of the extent to which patients with atopic dermatitis are affected by severe acne and isotretinoin tolerability are lacking. The aim of this study is to investigate isotretinoin therapy in patients with atopic dermatitis and to compare the nationwide prevalence with individuals without atopic dermatitis. All Norwegian residents were followed for 17 years until age 20–22 years in 2020. Approximately 28% of patients with atopic dermatitis had been treated for acne, and 8% had received isotretinoin before age 23 years. In those over 17 years old, significantly more patients with atopic dermatitis were treated with isotretinoin than those without. At age 22 years, 2.21% (95% confidence interval 1.92–2.49) of patients with atopic dermatitis were treated with isotretinoin, compared with 1.55% (95% confidence interval 1.44–1.65) of those without, representing 42.8% (1.43; 95% confidence interval 1.24–1.65) higher use in patients with atopic dermatitis. Patients who received long-term treatment (probable severe atopic dermatitis) tolerated isotretinoin similarly to patients who received short-term treatment (probable mild atopic dermatitis). There was significantly higher use of topical corticosteroids during isotretinoin therapy in patients with atopic dermatitis. Conclusively, severe acne (isotretinoin therapy) was associated with atopic dermatitis at the population level in young adults. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Narrowband-ultraviolet B vs Broadband-ultraviolet B in Treatment of Chronic Pruritus: A Randomized, Single-blinded, Non-inferiority Study.
- Author
-
KUPSA, Romana, GRUBER-WACKERNAGEL, Alexandra, HOFER, Angelika, QUEHENBERGER, Franz, WOLF, Peter, and LEGAT, Franz J.
- Subjects
- *
ITCHING , *SLEEP interruptions , *CHRONIC kidney failure , *VISUAL analog scale , *ATOPIC dermatitis - Abstract
Narrowband-ultraviolet B has shown increased efficacy over broadband-ultraviolet B in pruritic skin diseases, such as psoriasis and atopic dermatitis. In patients with chronic pruritus, e.g. in end-stage renal disease, broadband-ultraviolet B is recommended, but narrowband-ultraviolet B has also shown efficacy in reducing pruritus. This randomized, single blinded, non-inferiority study investigated the effects of narrowband-ultraviolet B compared with broadbandultraviolet B. Patients with chronic pruritus were treated with either broadband- or narrowband-UVB 3 times a week for 6 weeks and clinical response was monitored. Pruritus, sleep disturbance, and the patients’ subjective overall response to treatment were evaluated by the patients on a visual analogue scale (0–10). Skin excoriations were evaluated by investigators on a 4-point scale (0–3). Both phototherapeutic modalities showed significant antipruritic activity (itch reduction 48% and 66.4%, respectively) by broadband-ultraviolet B and narrowband-ultraviolet B. Narrowband-ultraviolet B proved to be not inferior to broadband-ultraviolet B in treating pruritus in patients with chronic pruritus, assuming a 20% noninferiority margin. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis.
- Author
-
Junfen ZHANG, LOMAN, Laura, OLDHOFF, Jantje M., and SCHUTTELAAR, Marie L. A.
- Subjects
- *
SOCIAL phobia , *ATOPIC dermatitis , *LONELINESS , *MENTAL illness , *ATTENTION-deficit hyperactivity disorder , *MEDICAL care , *CONSCIOUSNESS raising - Abstract
There is a lack of knowledge concerning loneliness and psychiatric disorders other than anxiety and depression in patients with atopic dermatitis. This cross-sectional study was conducted within the Lifelines Cohort Study, in the Netherlands, by sending an atopic dermatitis questionnaire to adult participants (n=135,950) in 2020. Psychiatric disorders were measured with a self-reported question and validated instrument (Mini International Neuropsychiatric Interview; M.I.N.I.), and loneliness was assessed with the validated 6-item De Jong Gierveld Loneliness Scale. In total, 56,896 subjects (mean age 55.8 years, 39.7% males) were included. Atopic dermatitis showed positive associations with self-reported chronic fatigue syndrome, burnout, depression, social phobia, panic disorder, attention deficit hyperactivity disorder, and eating disorder in the participants’ lifetimes. Based on the M.I.N.I., atopic dermatitis was positively associated with panic disorder and at least 1 anxiety disorder. In addition, subjects with atopic dermatitis were more likely to experience loneliness compared with those without atopic dermatitis. These associations were observed only in the moderate-to-severe, but not mild, atopic dermatitis group. This study raises awareness that a significant proportion of adults with atopic dermatitis feel lonely and are affected by several psychiatric disorders, especially those severely affected by atopic dermatitis. Further studies are required to evaluate if interdisciplinary care, such as the collaboration between dermatologists and psychiatrists, could optimize medical care for this vulnerable patient group. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy.
- Author
-
ALSTERHOLM, Mikael, SVEDBOM, Axel, ANDERSON, Chris D., SOMMAR, Lena HOLM, IVERT, Lina U., JOSEFSON, Anna, KOBYLETZKI, Laura von, LINDBERG, Magnus, LUNDEBERG, Lena, LUNDQVIST, Maria, NYLANDER, Elisabet, FALK, MariHelen SANDSTRÖM, SHAYESTEH, Alexander, SIGURDARDOTTIR, Gunnthorunn, SONESSON, Andreas, SVENSSON, Åke, VIRTANEN, Marie, VRANG, Sophie, WAHLGREN, Carl-Fredrik, and BRADLEY, Maria
- Subjects
- *
ATOPIC dermatitis , *MEDICAL registries , *DRUG therapy , *QUALITY of life , *ECZEMA - Abstract
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
- Author
-
BOESJES, Celeste M., VAN DER GANG, Liana F., ZUITHOFF, Nicolaas P. A., BAKKER, Daphne S., SPEKHORST, Lotte S., HAECK, Inge, KAMSTEEG, Marijke, de GRAAF, Marlies, and DE BRUIN-WELLER, Marjolein S.
- Subjects
- *
ATOPIC dermatitis , *DUPILUMAB , *BARICITINIB , *ACNEIFORM eruptions , *HERPES simplex - Abstract
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index ≤7 and Numerical Rating Scale – pruritus ≤4 were 73.0% (53.7–86.3) and 69.4% (48.7–84.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and/or baricitinib and in patients who were naïve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n=10, 21.3%), herpes simplex (n=6, 12.8%), nausea and airway infections (both n=4, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and/ or baricitinib treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Factors Associated with Eczema Clinical Trial Awareness, Interest, and Participation in Adults.
- Author
-
GRINICH, Erin E., THIBAU, Isabelle J., LATOUR, Emile, PRICE, Kyla N., LOISELLE, Allison R., SIMPSON, Eric, and BEGOLKA, Wendy SMITH
- Subjects
- *
CLINICAL trials , *ECZEMA , *PARTICIPATION , *SUBURBS , *ADULTS - Abstract
Despite the need for improved eczema therapies and a rapid increase in available eczema clinical trials, participation remains low. The aim of this study was to identify factors associated with clinical trial awareness, interest, and barriers to enrolment and participation. An online survey, administered 1 May to 6 June 2020 to adults (≥18 years) with eczema in the USA, was analysed. Among 800 patients included, mean age was 49.4 years, most respondents were female (78.1%), White (75.4%), non-Hispanic (91.4%), and geographically living in an urban/suburban area (Rural-Urban Continuum Codes (RUCC) 1–3, 90.8%). Only 9.7% of respondents reported previous participation in clinical trials, while 57.1% had considered participation and 33.2% never considered participation. Higher satisfaction with current eczema therapy, clinical trial literacy, and confidence in finding eczema trial information were all associated with clinical trial awareness, interest, and successful participation. Younger age and having atopic dermatitis were associated with increased awareness, while female gender was a barrier to interest and successful participation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Therapeutic Effect of Dupilumab on Systemic and Vascular Inflammation in Adults with Severe Atopic Dermatitis: Feasibility Study Using 18F-Fluorodeoxyglucose Positron Emission TomographyComputed Tomography.
- Author
-
Gi-Wook LEE, Keunyoung KIM, Seong-Jang KIM, Kihyuk SHIN, Hoonsoo KIM, Hyun-Chang KO, Moon-Bum KIM, and Byungsoo KIM
- Subjects
- *
POSITRON emission tomography , *POSITRON emission tomography computed tomography , *ATOPIC dermatitis , *DUPILUMAB , *TREATMENT effectiveness - Abstract
Atopic dermatitis (AD) is an inflammatory skin disease associated with increased systemic and vascular inflammation. Although dupilumab has been proven to be effective against severe AD, imaging studies analysing its inflammation-reducing effect have rarely been reported. The aim of this study was to evaluate the effect of dupilumab on systemic and vascular inflammation in adult patients with severe AD, using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT). A total of 33 adult patients with severe AD and 25 healthy controls underwent 18F-FDG PET/CT at baseline. Patients on dupilumab treatment underwent 18F-FDG PET/CT again after achieving a 75% reduction from baseline on the Eczema Area and Severity Index (EASI-75). Patients with AD exhibited increased 18F-FDG uptake values in the liver, spleen, pancreas, and carotid artery compared with healthy controls. However, compared with baseline, there was no statistically significant difference in 18F-FDG uptake in major organs and arteries after achieving EASI-75 with dupilumab treatment. In conclusion, while dupilumab treatment resulted in a significant clinical improvement and reduced serum inflammatory markers in adult patients with severe AD, no changes in systemic and vascular inflammation were observed on 18F-FDG PET/CT imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Effects of Early Emollient Use in Children at High Risk of Atopic Dermatitis: A German Pilot Study.
- Author
-
HARDER, Inken, STÖLZL, Dora, SANDER, Nicole, HARTMANN, Jan, RODRIGUEZ, Elke, MAZUR, Carsten, KERZEL, Sebastian, KABESCH, Michael, KÜSTER, Denise, SCHMITT, Jochen, FÖLSTER-HOLST, Regina, GERDES, Sascha, EMMERT, Hila, and WEIDINGER, Stephan
- Subjects
- *
ATOPIC dermatitis , *SKIN physiology , *PILOT projects , *SKIN examination - Abstract
Several small studies have indicated that daily emollient use from birth might delay, suppress or prevent atopic dermatitis (AD). Two larger trials did not confirm this; however, a recent smaller study indicated a protective effect if daily emollient use is used in the first 2 months of life. Further research is needed to evaluate the effect of emollient use on development of AD. The current study randomly assigned 50 newborns who were at high risk of developing AD (1:1) to receive general infant skin-care advice (control group), or skin-care advice plus emollient with advice to apply emollient at least once daily until 1 year of age (intervention group). Repeated skin examinations, skin physiology measurements and skin microbiome profiling were performed. Of the children in the intervention and control groups, 28% and 24%, respectively, developed AD (adjusted Relative Risk (RR) 1.19, p=0.65, adjusted risk difference 0.05). Skin pH decreased and transepidermal water loss and stratum corneum hydration increased over time in both groups with no significant differences. In the intervention group skin microbiome alpha diversity increased earlier, and the abundance of Streptococcus and Staphylococcus species were significantly reduced at month 1. Daily early emollient use in children with high risk of AD was safe, but it did not significantly reduce the risk of developing AD or impact skin physiology development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. The Treat-to-Target Project in Atopic Dermatitis: One Year On.
- Author
-
DE BRUIN-WELLER, Marjolein, DELEURAN, Mette, BIEDERMANN, Tilo, BISSONNETTE, Robert, FOLEY, Peter, GIROLOMONI, Giampiero, HERCOGOVÁ, Jana, HONG, Chih-Ho, KATOH, Norito, PINK, Andrew E., RICHARD, Marie-Aleth, SHUMACK, Stephen, SILVESTRE, Juan F., THYSSEN, Jacob P., and WEIDINGER, Stephan
- Subjects
- *
ATOPIC dermatitis , *CHRONIC diseases - Abstract
Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Itch and Janus Kinase Inhibitors.
- Author
-
Yujin HAN, Yu Ri WOO, Sang Hyun CHO, Jeong Deuk LEE, and Hei Sung KIM
- Subjects
- *
ITCHING , *KINASE inhibitors , *CREATINE kinase , *LICHEN planus , *ATOPIC dermatitis , *AUTOIMMUNE diseases - Abstract
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a signalling mechanism that regulates gene expression through various cytokines. Janus kinase inhibitors, which have been tested and used for several autoimmune diseases, have also been shown to be effective for itch through clinical trials and case reports. Janus kinase inhibitors could be a good choice for pruritus in atopic dermatitis, psoriasis, and other diseases, such as prurigo nodularis and lichen planus, with rapid itch relief compared with conventional treatments. The most common adverse effects reported include nasopharyngitis, acne, and elevated blood creatine phosphokinase levels. Janus kinase inhibitors are currently prescribed with warnings about a potential increase in malignancies and cardiovascular diseases and usage in people of older ages. This review aims to provide knowledge about itch and the Janus kinase and signal transducer and activator of transcription pathway and to analyse the current evidence for itch relief by Janus kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Impact of Atopic Dermatitis on Patients and their Partners.
- Author
-
MISERY, Laurent, SENESCHAL, Julien, CORGIBET, Florence, HALIOUA, Bruno, MARQUIÉ, Adrien, MERHAND, Stéphanie, LEFUR, Gaelle, STAUMONT-SALLE, Delphine, BERGQVIST, Christina, TAIEB, Charles, EZZEDINE, Khaled, and RICHARD, Marie-Aleth
- Subjects
- *
ATOPIC dermatitis , *EPWORTH Sleepiness Scale , *FRENCH people , *LUST , *INSOMNIACS , *SKIN diseases - Abstract
Atopic dermatitis is a chronic, relapsing and inflammatory skin disease. The impact of atopic dermatitis on the partners living with patients has been poorly investigated. The objective of this study was to evaluate the impact of atopic dermatitis in the daily lives of adult patients and to assess the burden of the disease on their partners. A population-based study was conducted on a representative sample of the general population of French adults aged 18 years of age using stratified, proportional sampling with a replacement design. Data were collected on 1,266 atopic dermatitis patient-partner dyads (mean age of patients 41.6 years, 723 (57.1%) women). The mean age of partners was 41.8 years. Patient burden, measured by the Atopic Dermatitis Burden Scale for Adults (ABS-A) score, was closely related to the objective atopic dermatitis severity: the mean score in the mild group (29.5) was significantly lower than in the moderate (43.9) and severe groups (48.6) (p<0.0001). Partner burden, measured by the EczemaPartner score, was highly related to atopic dermatitis severity (p<0.0001). Daytime sleepiness, measured by the Epworth Sleepiness Scale, showed a mean score of 9.24 in patients and 9.01 in their partners, indicating impaired sleep. Atopic dermatitis was found to decrease sexual desire in 39% and 26% of partners and patients respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Happiness Behind the Scenes: Associations between Heuristic Happiness and Related Dimensions in Skin Diseases.
- Author
-
WEIS, Johanna, WECKER, Hannah, ARNOLD, Alexander, SCHUSTER, Barbara, ZIEHFREUND, Stefanie, TIZEK, Linda, MITTAG, Sonja, BIEDERMANN, Tilo, and ZINK, Alexander
- Subjects
- *
SKIN diseases , *HAPPINESS , *LIFE satisfaction , *ATOPIC dermatitis , *AFFECT (Psychology) - Abstract
Positive health approaches, such as happiness, are largely unexplored in medicine, including dermatology. Taking into consideration the various happiness measures, the aims of this cross-sectional study were to assess this concept using a 1-item heuristic happiness question and its related dimensions (Satisfaction with Life, Positive and Negative Affect, Quality of Life, and Compound Psychological Capital) in outpatients with different skin diseases between December 2019 and June 2020, and to examine the link between these dimensions. Overall, 414 dermatological patients were included: 67 with psoriasis, 84 atopic eczema, 10 mastocytosis, 19 nummular eczema, 84 malignant melanoma and 150 keratinocyte carcinoma. Comparing the skin diseases, differences were observed for heuristic happiness, Positive Affect, and some domains of Quality of Life and Compound Psychological Capital. Analysing the relationship between heuristic happiness and other happiness measures, the data revealed moderate to strong correlations (r=0.30–0.46, p<0.001) and variations in the understanding of happiness between the skin diseases. Overall, the most important facet of happiness was Hope as a domain of Compound Psychological Capital. This study emphasizes the individual definition of heuristic happiness in patients with skin diseases. A 1-item heuristic approach may be a simple and practical method to assess the complexity and individuality of happiness. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Effect of Paediatric Atopic Dermatitis on Parental Sleep Quality.
- Author
-
FORER, Ester, TRIPTO, Inbal GOLAN, BARI, Romi, SHAKI, David, GOLDBART, Aviv, and HOREV, Amir
- Subjects
- *
SLEEP quality , *ATOPIC dermatitis , *SLEEP latency , *SLEEP interruptions , *SLEEP duration - Abstract
Data on the impact of paediatric atopic dermatitis on parental sleep are scarce. The aim of this study was to examine the effects of paediatric atopic dermatitis on the quality of parents’ sleep. This cross-sectional study included parents of patients with atopic dermatitis and parents of healthy children who completed validated Pittsburgh Sleep Quality Index questionnaires. The study and control groups were compared, as were results for mild and moderate atopic dermatitis with severe atopic dermatitis, mothers and fathers, and different ethnic groups. A total of 200 parents were enrolled. Sleep latency was significantly longer in the study group compared with the control group. Sleep duration was shorter in the parents of the mild AD group compared with the moderate-severe and control groups. Parents in the control group reported more daytime dysfunction than parents in the AD group. Fathers of children with AD reported more sleep disturbance than mothers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Economic Burden of Atopic Dermatitis in Taiwan.
- Author
-
Ellen M. LEE, Yung-Tsu CHO, Tom C. CHAN, Dereck SHEN, Chia-Yu CHU, and Chao-Hsiun TANG
- Subjects
- *
ATOPIC dermatitis , *ECZEMA , *NATIONAL health insurance , *GROSS domestic product , *SKIN diseases , *ECONOMIC aspects of diseases - Abstract
Atopic dermatitis is a prevalent inflammatory skin disease that manifests clinically as pruritus and eczema. Severe forms of atopic dermatitis can be chronic and relapsing or associated with other dermatological complications and comorbidities, resulting in lifelong impacts across multiple aspects for patients. This study was conducted to calculate the atopic dermatitis-related economic burden in Taiwan. First, the out-ofpocket costs incurred by 200 patients with atopic dermatitis were estimated using a specifically designed questionnaire. Secondly, work impairment was converted into quantifiable costs. The costs reimbursed by the Taiwan National Health Insurance (NHI), which were estimated in our previous work, were included in the final calculation. The atopic dermatitis-related economic burden for patients in Taiwan in 2018 was estimated as (2018 New Taiwan dollars; NT$) 37.90 billion, which is 0.207% of Taiwan’s gross domestic product. This substantial economic burden suggests an existing need for more effective and equitable treatment for atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis.
- Author
-
ACHTEN, Roselie, VAN DER RIJST, Lisa, PIENA, Marjanne, LAMERS, Hedda, DE BEER, Fleur, DE BRUINWELLER, Marjolein, and DE GRAAF, Marlies
- Subjects
- *
CHILD patients , *ATOPIC dermatitis , *PATIENT reported outcome measures - Abstract
Data concerning the economic and humanistic burden in patients with paediatric atopic dermatitis (AD) and their families are scarce. This retrospective study investigated these burdens in paediatric patients with AD using maintenance treatment with topical corticosteroids and/or conventional systemic immunosuppressants. Patient-reported outcomes regarding quality of life, AD severity, and parental work-related impairment were completed at inclusion. Data on healthcare resource utilization and medication prescription were collected retrospectively over the previous 12 months. Patients were categorized into mild, moderate or severe AD, based on Eczema Area and Severity Index score and medication use. Costs per patient per year per AD severity category were calculated. A total of 101 patients (median age 11.0 years (interquartile range 7.5–14.0), 47.5% men) were included, of whom 38 had mild AD, 37 moderate AD, and 26 severe AD. Mean±standard deviation (SD) total costs patient per year for mild, moderate and severe AD were €1,812±€1,280, €2,680±€3,127, and €5,861± €3,993, respectively. Highest total direct and indirect costs were found in patients with severe AD, mainly due to higher healthcare and medication costs. Highest humanistic burden was found in patients with moderate AD. For example, the median (interquartile range) Patient-Oriented Eczema Measure score was significantly higher in these patients compared with mild and severe AD (19.0 (15.0–24.0) vs 12.0 (8.8– 15.0) and 17.0 (9.5–22.0), respectively). AD in paediatric patients incurs considerable direct and indirect costs, especially in patients with severe AD. The high humanistic burden in patients with moderate AD underlines the need for effective and safe new treatment options for children with AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Increased Risk of Dementia in Patients with Atopic Dermatitis: A Nationwide Population-Based Cohort Study.
- Author
-
Yu Ri WOO, Minah CHO, Kyung Do HAN, Sang Hyun CHO, and Ji Hyun LEE
- Subjects
- *
DISEASE risk factors , *DEMENTIA patients , *ATOPIC dermatitis , *ALZHEIMER'S disease , *VASCULAR dementia , *NATIONAL health insurance - Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with bimodal incidence peaks in early childhood and middle-aged and older adults. Few studies have focused on the risk of dementia in AD. The aims of this study were to analyse the incidence, and risk factors for dementia in patients with AD. This nationwide population-based retrospective cohort study enrolled 38,391 adults ≥40 years of age with AD and 2,643,602 controls without AD from the Korean National Health Insurance System (NHIS) database from 2009 to 2016. The cumulative incidence probability of all-cause dementia, Alzheimer’s disease, or vascular dementia at 8 years was 50, 39, and 7 per 1,000 person-years in patients with AD, respectively. The adjusted risks of all-cause dementia (hazard ratio (HR), 1.072; 95% confidence interval (95% CI) 1.026– 1.120), and Alzheimer’s disease (HR 1.051; 95% CI 1.000–1.104) were increased in patients with AD. The effect of AD on the development of all-cause dementia and Alzheimer’s dementia varied according to age and diabetes mellitus (all p for interaction, <0.05). The risks of all-cause dementia and Alzheimer’s disease were increased in patients with AD. Management of modifiable risk factors is important for preventing dementia in patients with AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Effect of Disease Severity on Comorbid Conditions in Atopic Dermatitis: Nationwide Registry-Based Investigation in Finnish Adults.
- Author
-
KIISKI, Ville, UKKOLA-VUOTI, Liisa, VIKKULA, Johanna, RANTA, Martta, LASSENIUS, Mariann I., and KOPRA, Jaakko
- Subjects
- *
ATOPIC dermatitis , *URTICARIA , *SOMATOFORM disorders , *ROSACEA , *COMORBIDITY , *HERPES zoster , *INTERVERTEBRAL disk - Abstract
The majority of registry studies on atopic dermatitis include only patients and diagnoses from specialized healthcare. The aim of this retrospective, real-world cohort study was to evaluate the effect of atopic dermatitis severity on comorbidities and total morbidity, with comprehensive data from both primary and specialty healthcare registries covering the entire Finnish adult population. In total, 124,038 patients were identified (median age 46 years; 68% female) and stratified by disease severity. All regression analyses (median follow-up 7.0 years) were adjusted at a minimum for age, sex, obesity, and educational level. Compared with mild atopic dermatitis, severe atopic dermatitis was significantly associated with multiple morbidities, including neurotic, stress-related and somatoform disorders, abscesses, erysipelas/cellulitis, impetigo, herpes zoster, extragenital herpes, bacterial conjunctivitis, septicaemia, lymphomas, alopecia areata, urticaria, other dermatitis, contact allergy, osteoporosis, and intervertebral disc disorders (p<0.001). In addition, there were significant associations with alcohol dependence, depression, condylomas, rosacea, migraine, sleep apnoea, hypertension, enthesopathies, atherosclerosis, and drug-induced cataract (p<0.05). Odds ratios were modest and mostly were between 1.10 and 2.75. Furthermore, patients with severe atopic dermatitis had lower incidences of prostate cancer, cystitis, and anogenital herpes than patients with mild atopic dermatitis (p<0.05). These results suggest that severe atopic dermatitis results in significant overall morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREAT germany.
- Author
-
WEISSHAAR, Elke, BENTZ, Philipp, APFELBACHER, Christian, HAUFE, Eva, HEINRICH, Luise, HERATIZADEH, Annice, ABRAHAM, Susanne, HARDER, Inken, KLEINHEINZ, Andreas, WOLLENBERG, Andreas, SCHÄKEL, Knut, WIEMERS, Franca, ERTNER, Julia, AUGUSTIN, Matthias, WILDBERGER, Julia, KIEDROWSKI, Ralph von, WORM, Margitta, ZINK, Alexander, EFFENDY, Isaak, and ASMUSSEN, Andrea
- Subjects
- *
ATOPIC dermatitis , *ITCHING , *PATIENT experience , *MEDICAL registries , *MENTAL depression , *QUALITY of life , *DERMATOLOGIC nursing - Abstract
TREATgermany is an investigator-initiated prospective disease registry. It investigates physician- and patient-reported disease severity (Eczema Area and Severity Index (EASI), objective Scoring Atopic Dermatitis (oSCORAD), Investigator Global Assessment, Patient-Oriented Eczema Measure (POEM), Patient Global Assessment (PGA)), patient-reported symptoms (itch, sleep loss, depressive symptoms), therapy courses and dermatological quality of life (DLQI) in moderate-to-severe atopic dermatitis with SCORAD >20. 1,134 atopic dermatitis patients (mean age 41.0±14.7 years, 42.5% females) were enrolled by 40 German recruiting sites (dermatological clinics and practices) between June 2016 and April 2021. The current analysis focuses on itch scores obtained with a numerical rating scale (NRS)) documented for the previous 3 days prior to baseline visit. The results show that 97.2% (1,090 of 1,121) patients experienced itch. Itch severity correlated moderately with severity of atopic dermatitis oSCORAD (rho=0.44 (0.39–0.48)) and EASI score (rho=0.41 (0.36–0.46)). A strong correlation was found with self-reported disease severity as PGA (rho=0.68 (0.65–0.71)), POEM sum score (rho=0.66 (0.63–0.69)) and dermatological quality of life impairment DLQI (rho=0.61 (0.57–0.65)). Itch as a subjective complaint is more closely correlated with patient-reported outcomes than with objective assessments by the physician. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. A Comparative Analysis of the Predictors, Extent and Impacts of Self-stigma in Patients with Psoriasis and Atopic Dermatitis.
- Author
-
SCHLACHTER, Sophie, SOMMER, Rachel, AUGUSTIN, Matthias, TSIANAKAS, Athanasios, and WESTPHAL, Lukas
- Subjects
- *
ATOPIC dermatitis , *PSORIASIS , *SOCIAL support , *COMPARATIVE studies , *CHRONICALLY ill - Abstract
The impact of dermatological diseases goes beyond symptoms and often includes psychosocial burden. Self-stigmatization plays a key role in this relationship and was compared in patients with psoriasis and atopic dermatitis to evaluate the validity of cross-disease stigmatization models. In total, 101 patients per indication were included in this cross-sectional study. Besides sociodemographic and clinical data, patientreported outcome measures relating to self-stigmatization, depression, anxiety, and quality of life were compared across groups. Sociodemographic and clinical factors were tested for their moderating effects between self-stigmatization and quality of life. Group mean comparisons yielded no significant differences in self-stigmatization between patient groups. In both diseases, self-stigmatization significantly predicted depression and anxiety symptoms as well as quality of life. Current symptoms, not having close social relationships, and lower age predicted self-stigma in patients with psoriasis, whereas the involvement of sensitive body areas, the sum of previous treatments, and female sex were predictors in patients with atopic dermatitis. In both groups, symptoms had significantly moderating effects. The results underline the relevance of self-stigmatization in patients with chronic skin diseases. Awareness should be raised, screening implemented, and psychosocial support offered early on. Assessments, conceptual models of self-stigma, and interventions are probably applicable for both diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Role of Mannose-binding Lectin and Association with Microbial Sensitization in a Cohort of Patients with Atopic Dermatitis.
- Author
-
BELFRAGE, Emma, JINNESTÅL, Camilla L., JÖNSEN, Andreas, BENGTSSON, Anders, ÅKESSON, Anna, SCHMIDTCHEN, Artur, and SONESSON, Andreas
- Subjects
- *
ATOPIC dermatitis , *IMMUNOGLOBULIN E , *LECTINS , *CANDIDA albicans , *GENETIC testing , *ODDS ratio - Abstract
Atopic dermatitis is a relapsing inflammatory skin condition, in which bacteria, fungi and viruses may colonize the skin and aggravate the condition. Mannosebinding lectin is part of the innate immune system. Polymorphism in the mannose-binding lectin gene can result in deficiency of mannose-binding lectin, which may affect defence against microbes. The aim of this study was to investigate whether polymorphisms in the mannose-binding lectin gene affect the extent of sensitization to common skin microbes, the skin barrier function, or the severity of the disease in a cohort of patients with atopic dermatitis. Genetic testing of mannose-binding lectin polymorphism was performed in 60 patients with atopic dermatitis. The disease severity, skin barrier function, and serum levels of specific immunoglobulin E against skin microbes were measured. In patients with low mannose-binding lectin genotype (group 1) 6 of 8 (75%) were sensitized to Candida albicans, compared to 14 of 22 (63.6%) patients with intermediate mannose-binding genotype (group 2) and 10 of 30 (33.3%) patients with high mannose-binding genotype (group 3). Group 1 (low mannose-binding lectin) was more likely to be sensitized to Candida albicans compared with group 3 (high mannose-binding lectin) (odds ratio 6.34, p-value 0.045). In this cohort of patients with atopic dermatitis, mannose-binding lectin deficiency was associated with increased sensitization to Candida albicans. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Psychological Stress in Parents of Children with Atopic Dermatitis: A Cross-sectional Study from the Korea National Health and Nutrition Examination Survey.
- Author
-
Hyun Ji LEE, Gyu-Na LEE, Ji Hyun LEE, Ju Hee HAN, Kyungdo HAN, and Young Min PARK
- Subjects
- *
ATOPIC dermatitis , *PSYCHOLOGICAL stress , *FATHER-child relationship , *PARENTS , *CROSS-sectional method , *MARITAL status - Abstract
Atopic dermatitis is a chronically relapsing inflammatory skin condition that has profound impacts on quality of life of patients and their family. The aim of this study is to investigate the psychological stress in parents of children with atopic dermatitis in Korea, using data from the Korean National Health and Nutrition Examination Survey (KNHANES). This cross-sectional study included parents of participants under 19 years of age (970 with atopic dermatitis and 5,733 without atopic dermatitis after excluding those who meet the exclusion criteria) from the 2009 to 2012 KNHANES. The psychological stress state was evaluated with the following four questionnaire items: self-perception of stress, depressed mood, suicidal ideation, and diagnosis of depression by a physician. After adjusting for age, gender, education level, occupation, and marital status, logistic regression analyses indicated that mothers of children with atopic dermatitis had a higher frequency of stress perception (adjusted odds ratio (aOR) 1.46 (95% confidence interval (95% CI) 1.22– 1.74), p<0.01) and suicidal ideation (aOR 1.40 (95% CI 1.1–1.79), p<0.01) than those without atopic dermatitis. In contrast, fathers of children with atopic dermatitis did not show a significant difference in all items compared with those of children without atopic dermatitis. Understanding the psychological stress in parents of children with atopic dermatitis is important for clinicians, since evaluation, management and support for parents, especially mothers, of children with atopic dermatitis are required. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis.
- Author
-
TANJI, Takayuki, WATABE, Daisuke, ARAKAWA, Nobuyuki, KAMADA, Hirofumi, and AMAN, Hiroo
- Subjects
- *
JUMPER'S knee , *ATOPIC dermatitis , *JOINT pain , *TENNIS elbow - Abstract
The article focuses on the successful treatment of arthralgia induced by a dual interleukin-4/interleukin-13 blocker (dupilumab) in a patient with atopic dermatitis using an oral Janus kinase inhibitor (upadacitinib). Topics include the pathophysiology of atopic dermatitis, the adverse effects of dupilumab leading to arthralgia, and the effectiveness of upadacitinib in controlling both skin lesions and joint symptoms.
- Published
- 2023
- Full Text
- View/download PDF
31. Preferences of Patients with Atopic Dermatitis Regarding Patient Self-administered Tools Used in Clinical Practice.
- Author
-
MANDELIN, Johanna M., EKMAN, Anna, RUOHONEN, Suvi T., and KORHONEN, Laura
- Subjects
- *
ATOPIC dermatitis , *PATIENT preferences , *ECZEMA , *CHILD patients , *MEDICAL personnel , *ALLERGIES - Abstract
The article focuses on patient preferences for self-administered tools in clinical practice for atopic dermatitis (AD), a chronic inflammatory skin disease. It study evaluates patients' choices between specific measurement tools (Patient-Oriented Eczema Measure (POEM), Atopic Dermatitis Control Tool (ADCT), and Dermatology Life Quality Index (DLQI)) in assessing AD severity and disease control, revealing that patients generally find both POEM and ADCT meaningful.
- Published
- 2023
- Full Text
- View/download PDF
32. ABSTRACTS from 12th Georg Rajka International Symposium on Atopic Dermatitis.
- Subjects
- *
ATOPY , *ECZEMA , *ATOPIC dermatitis , *MEDICAL personnel , *CCD cameras , *LIQUID chromatography-mass spectrometry - Published
- 2022
- Full Text
- View/download PDF
33. Characterization of Classical Flexural and Nummular Forms of Atopic Dermatitis in Childhood with Regard to Anamnestic, Clinical and Epidermal Barrier Aspects.
- Author
-
HÜPPOP, Folke, DÄHNHARDT-PFEIFFER, Stephan, and FÖLSTER-HOLST, Regina
- Subjects
- *
ATOPIC dermatitis , *MICROSCOPY , *KERATOSIS , *THERAPEUTICS , *ECZEMA - Abstract
Nummular (coin-shaped) and classical (flexural) atopic dermatitis differ morphologically, but no other distinguishing features are known. The aim of this study was to determine differences and similarities of both variants in children. Detailed interviews, clinical examinations, biophysical measurements and electron microscopic analyses were performed on 10 children with nummular atopic dermatitis, 14 with classical atopic dermatitis and 10 healthy controls. Nummular atopic dermatitis affected more boys than girls and manifested less frequently within the first year of life than classical atopic dermatitis. Localization, distribution and morphology of the eczema varied more over time, and expression of keratosis pilaris was more severe in children with nummular atopic dermatitis. Both disease groups showed reduced hydration, increased transepidermal water loss and reduced intercellular lipid lamellae in lesional skin areas compared with non-lesional areas. These findings underline the separate classification of both variants. Further research is necessary to investigate the potential of diverging therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
- Author
-
ACHTEN, Roselie E., VAN LUIJK, Chantal M., VAN DER RIJST, Lisa P., BAKKER, Daphne S., SPEKHORST, Lotte S., ZUITHOFF, Nicolaas P. A., SCHUTTELAAR, Marie L. A., ROMEIJN, Geertruida L. E., VOORBERG, Angelique N., KAMSTEEG, Marijke, HAECK, Inge M., DE GRAAF, Marlies, THIJS, Judith L., DE BOER, Joke H., and DE BRUIN-WELLER, Marjolein S.
- Subjects
- *
ATOPIC dermatitis , *ALLERGIC conjunctivitis , *LOGISTIC regression analysis , *EYE diseases , *DUPILUMAB , *MULTIVARIATE analysis - Abstract
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupilumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30-11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Living with Atopic Dermatitis as a Young Adult in Relation to Healthrelated Quality of Life and Healthcare Contacts: A Population-based Study.
- Author
-
LUNDIN, Susanne, BERGSTRÖM, Anna, WAHLGREN, Carl-Fredrik, JOHANSSON, Emma K., ANDERSSON, Niklas, BALLARDINI, Natalia, JONSSON, Marina, MELÉN, Erik, and KULL, Inger
- Subjects
- *
ATOPIC dermatitis , *YOUNG adults , *QUALITY of life , *MEDICAL care , *DATA warehousing - Abstract
Most studies of health-related quality of life (HRQoL) and atopic dermatitis are based on data from dermatology clinics. The aim of this study was to determine whether atopic dermatitis affects HRQoL in adolescence and young adulthood, based on data from the population-based cohort BAMSE (Children, Allergy, Environmental, Stockholm, Epidemiology). A further aim was to determine if the use of topical corticosteroids and healthcare contacts affect HRQoL. Participants with data from birth to young adulthood (n=3,064) were included. Two generic instruments were used to measure HRQoL:General Health at age 12, 16 and 24 years and EQ-5D-3L, including EQ-visual analogue scale (EQ-VAS) at age 24 years. In addition, the diseasespecific Dermatology Quality Life Index (DLQI) was used at 24 years. Healthcare consultations for atopic dermatitis were obtained from Stockholm Regional Healthcare Data Warehouse (n = 1,944). Participants with atopic dermatitis had an increased odds ratio (OR) of not feeling completely healthy (adjusted OR 1.50; 95% confidence interval (95% CI): 1.30-1.73). Participants with persistent atopic dermatitis, fulfilling atopic dermatitis criteria in the 12- and/or 16- and 24-year follow-ups reported worse EQ-VAS value 70.0 (95% CI 67.3-72.7) in the 25th percentile, than peers without atopic dermatitis. Over an 8-year period, contact with healthcare was limited (mean number 0.96). In conclusion, atopic dermatitis had a negative impact on HRQoL in young adults from adolescence to adulthood and healthcare consultations were few. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis.
- Author
-
WOLLENBERG, Andreas, MARCOUX, Danielle, SILVERBERG, Jonathan I., AOKI, Valeria, BASELGA, Eulalia, ZHANG, Haixin, LEVIT, Noah A., TAIEB, Alain, and ROSSI, Ana B.
- Subjects
- *
CHILD patients , *ATOPIC dermatitis , *DUPILUMAB , *TREATMENT effectiveness , *AGE groups - Abstract
This post hoc analysis examined SCORing Atopic Dermatitis (SCORAD) outcomes in 471 paediatric patients (children age 6-<12 years, n = 304; adolescents age 12-<18 years, n = 167) with atopic dermatitis treated with dupilumab, ± topical corticosteroids, in two 16-week phase 3 randomized controlled trials and a 1-year interim data cut of a subsequent open-label extension study. Paediatric patients treated with dupilumab (± topical corticosteroids) had significantly lower SCORAD, objective SCORAD (o-SCORAD), and individual SCORAD components from week 3 to 16 compared with placebo (± topical corticosteroids) in the randomized controlled trials. The results were sustained or continuously improved over 1 year of open-label treatment with dupilumab ± topical corticosteroids. SCORAD-50 was achieved in almost all patients (91.3-91.8%) by week 52 with continued dupilumab treatment across age groups. Almost all (> 86%) patients achieved mild or absent pruritus and sleep loss at week 52. In conclusion, dupilumab ± topical corticosteroids resulted in rapid and significant improvements in all aspects of SCORAD analysed, and the results were sustained over 1 year. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Age-dependent Distribution of Atopic Dermatitis in Primary Care: A Nationwide Population-based Study from Finland.
- Author
-
SALAVA, Alexander, RIEPPO, Ruut, LAUERMA, Antti, and SALO, Ville
- Subjects
- *
ATOPIC dermatitis , *PRIMARY care , *OLDER patients , *FILAGGRIN , *AGE groups , *GENERAL practitioners - Abstract
The burden of atopic dermatitis (AD) appears to be increasing in adult and elderly patients. The aim of this study was to analyse the nationwide database of the Finnish Institute for Health and Welfare regarding the number of patients with AD and of general practitioner consultations in Finland during 2018. The database comprised the main diagnoses of all visits to public primary healthcare. There were 2,094,673 primary care patients (males/females 43.19/56.81%) and 20,905 patients with AD (1.00%) and 24,180 consultations due to AD (0.45%). The highest numbers of patients with AD were in the age groups 0-14 years (9,922 patients, 47.46%) and 15-65 years (9,144 patients, 43.74%). A substantial proportion of patients with AD were aged > 50 years (3,515 patients, 16.81%) or >65 years (1,947 patients, 9.31%). Regression analysis indicated a statistically significant association of age group with patient numbers (p = 0.032) and number of consultations (p = 0.030). There were no differences between direct age group comparisons (p = 0.303), sex (p = 0.389), or number of consultations/patient (p = 0.235). Patients with AD are prevalent in all age groups in Finnish primary care. Patient numbers were also relatively high in groups other than childhood, indicating that age-related distribution in primary care may be shifting to older ages. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Differences in Occurrence, Risk Factors and Severity of Early-onset Atopic Dermatitis among Preterm and Term Children.
- Author
-
GERNER, Trine, RINNOV, Maria Rasmussen, HALLING, Anne-Sofie, RAVN, Nina Haarup, KNUDGAARD, Mette Hjorslev, EWERTSEN, Caroline, TRAUTNER, Simon, JAKASA, Ivone, KEZIC, Sanja, SKOV, Lone, and THYSSEN, Jacob P.
- Subjects
- *
ATOPIC dermatitis , *GENETIC mutation , *AGE of onset , *ENVIRONMENTAL risk , *ENVIRONMENTAL exposure - Abstract
This prospective birth cohort followed 150 preterm and 300 term newborns during the first year of life to assess possible differences in risk factors, age at onset, anatomical location, and severity of atopic dermatitis. Atopic dermatitis was diagnosed clinically, and severity was assessed using Eczema Area Severity Index (EASI). DNA was analysed for filaggrin gene mutations. Parents were asked about environmental exposures and emollient use. Atopic dermatitis during the first year of life was observed in 21.2% of children and was more common in term children compared with preterm children (26.7% vs 11.7%, p < 0.001), with lower age of onset (4 vs 6 months, p < 0.05) and more severe disease at onset (EASI: 4.8 vs 0.4, p < 0.0005). Environmental risk factors for atopic dermatitis were essentially similar for preterm and term born children, apart from winter and autumn births. Filaggrin gene mutations were less common in preterm than term children (4.1% vs 9.2%, p = 0.06). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry.
- Author
-
LARSEN, Henrik H. P., VITTRUP, Ida, RUGE, Iben F., ELBERLING, Jesper, SKOV, Lone, IBLER, Kristina, JEMEC, Gregor B. E., MORTZ, Charlotte G., BACH, Rasmus O., BINDSLEV-JENSEN, Carsten, DALAGER, Maiken G., AGNER, Tove, DELEURAN, Mette, VESTERGAARD, Christian, and THYSSEN, Jacob P.
- Subjects
- *
ATOPIC dermatitis , *QUALITY of life , *AGE of onset , *ECZEMA , *ITCHING - Abstract
Data from real-world use of new systemic treatments in atopic dermatitis (AD) is important for assessing safety and efficacy. The aim of this study is to describe the baseline characteristics of adult patients with moderate-to-severe AD enrolled in the Danish nationwide Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) database, between October 2017 and August 2021. A total of 282 adult patients were included. Most (62%) were men, the median age at baseline was 43 years (interquartile range (IQR) 29-54 years), and median age at onset of AD was 1 year (IQR 0-6 years). The median Eczema Area and Severity Index at treatment initiation was 19.1 (IQR 11.9-25.7); median Patient Oriented Eczema Measure 21.0 (IQR 16.0-25.0); median Dermatology Life Quality Index 13.0 (IQR 7.0-19.0); and median itch and sleep numerical rating scale scores 8.0 (IQR 6.0-9.0) and 6.0 (IQR 4.0-8.0). Differences were found between the sexes. This registry will provide a source for future efficacy and safety studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Treatment Patterns among Patients with Atopic Dermatitis in Secondary Care: A National, Observational, Non-interventional, Retrospective Study in Sweden.
- Author
-
JOHANSSON, Emma K., BRENNECHE, Andreas, TRANGBAEK, Dennis, STELMASZUK, M. Natalia, FREILICH, Jonatan, and ANDERSON, Chris D.
- Subjects
- *
ATOPIC dermatitis , *SECONDARY care (Medicine) , *DUPILUMAB , *REGIONAL differences , *RETROSPECTIVE studies - Abstract
This non-interventional, observational, longitudinal study describes treatment patterns of atopic dermatitis (AD) in Sweden. Data from 3 Swedish registries were merged, and included patients who received an AD diagnosis (during the period 1997 to 2019) and had AD treatment prescribed (during the period 2006 to 2020). Treatment persistence, treatment sequencing, time-to-event analysis, and 12-month prevalence were analysed. Overall, data for 99,885 patients with AD were included, of whom 4,086 (4.1%) received systemic treatments. Median persistence rates were 12.6 (95% CI 11.9, 13.4) months for methotrexate, 10.8 (9.1, 13.0) months for azathioprine, 5.6 (3.8, 6.2) months for mycophenolate, 5.1 (4.4, 5.7) months for alitretinoin and 3.4 (3.2, 3.7) months for cyclosporine. Median (Q1, Q3) time from first secondary care visit for AD to first systemic treatment was 5.8 (2.2, 11.0) years overall and 4.4 (1.3, 9.1) years in the Stockholm region. Methotrexate was a prominent first- and second-line treatment used during the period 2006 to 2020. Dupilumab was introduced during the study period and was increasingly used as first- or secondline therapy over time. The 12-month prevalence of AD generally remained steady, with a gradual increase observed over time for the overall population. A steep increase was observed in Stockholm from 2011. This study shows that a small proportion of patients with AD are offered systemic treatments in Sweden, with long periods in secondary care prior to systemic treatments and low persistence on systemic treatments. Regional differences highlight a need for national treatment guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study.
- Author
-
IVERT, Lina U., SVEDBOM, Axel, LUNDQVIST, Maria, WAHLGREN, Carl-Fredrik, BRADLEY, Maria, and JOHANSSON, Emma K.
- Subjects
- *
ATOPIC dermatitis , *MENTAL depression , *COHORT analysis , *SUICIDAL ideation , *QUALITY of life - Abstract
Information on depressive symptoms among patients with atopic dermatitis (AD) undergoing systemic treatment in a real-world setting is scarce. This prospective real-world clinical cohort study analysed data from SwedAD, a Swedish national register comprising patients with AD undergoing systemic treatment. Data were collected at baseline (n = 120) and at follow-up at 6 months (range 3-9 months, n = 59), and 12 months (10 months or later, n = 36). Depression was assessed with the Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S) and AD with the Eczema Area Severity Index, the Patient-Oriented Eczema Measure, the Dermatology Life Quality Index and evaluation of pruritus. More than half of patients with moderate-to-severe AD had depressive symptoms at baseline, 24% presented with moderate-to-severe depression and 3% had pronounced suicidal ideation. Systemic treatment of AD significantly reduced both depression and AD symptoms at 6 months, and this positive effect remained at 12 months. In conclusion, depressive symptoms are common among adults with moderate-to-severe AD. Systemic treatment of AD significantly reduced depressive symptoms in parallel with AD symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Eczema-related Web Search Data in Sweden: Investigating Search Patterns and the Influence of Weather.
- Author
-
TIZEK, Linda, WECKER, Hannah, SCHNEIDER, Simon, JOHANSSON, Emma K., GIRMAY, Yodit, and ZINK, Alexander
- Subjects
- *
INTERNET searching , *SEARCH engines , *ATOPIC dermatitis , *WEATHER , *ECZEMA - Abstract
As atopic eczema is triggered by environmental factors, such as temperature, differences in disease burden between and within countries are possible. One method to study this phenomenon is to perform websearch analysis, since the internet is commonly used to retrieve health-related information. This study, investigating the Google search volume regarding eczema in Swedish counties between April 2017 and March 2021, revealed a continuous increase in number of searches and that the search volume was higher in Northern than Southern Sweden. Gotland had the most searches per 100,000 inhabitants. In general, there was a negative correlation between search volume and temperature (r=-0.315, p < 0.001) and hours of sunshine (r=-0.213, p < 0.001), whereas there was a positive association between search volume and wind (r=0.229, p < 0.001). Search engine analysis is a rapid and cost-effective method of examining search behaviour regarding disease among the general population within a country and, thus, can enable the identification of regions with specific interests and needs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. No Association Between First Exposure to General Anaesthesia and Atopic Dermatitis in the Paediatric Population.
- Author
-
Dong Chan KIM, Young Woong CHOI, Eun-So LEE, and Jee Woong CHOI
- Subjects
- *
CHILD patients , *ATOPIC dermatitis , *ANESTHESIA , *CONFIDENCE intervals - Abstract
General anaesthesia could affect various immune responses, including Th1 and Th2 immunity, which might also affect cells that play an important role in the pathogenesis of atopic dermatitis. However, the relationship between general anaesthesia exposure and atopic dermatitis remains unknown. The aim of this study was to investigate the risk of developing atopic dermatitis after first exposure to general anaesthesia in the paediatric population (18 years or under). A retrospective cohort study, including those exposed (n = 7,681) and unexposed (n = 38,405; control participants) to general anaesthesia (1:5 ratio), was conducted using national sample cohort data from 2002 to 2015. All participants were followed up for 2 years after cohort entry. The 2-year cumulative incidences of atopic dermatitis in the exposed and unexposed groups were 2.3% and 2.2%, respectively. In the subgroup analysis by age, the cumulative incidence was not significantly different between these cohorts. The risks of atopic dermatitis were not significant in the exposed group in the univariate model (hazard ratio 1.05; confidence interval 0.88-1.24) and in the multivariate model, wherein all covariates were adjusted (adjusted hazard ratio, 1.03; 95% confidence interval 0.87-1.23). The results suggest that children's exposure to general anaesthesia was not associated with increased or decreased risk of atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
- Author
-
BOESJES, Celeste M., KAMPHUIS, Esmé, ZUITHOFF, Nicolaas P. A., BAKKER, Daphne S., LOMAN, Laura, SPEKHORST, Lotte S., HAECK, Inge, KAMSTEEG, Marijke, VAN LYNDEN-VAN NES, Anneke M. T., GARRITSEN, Floor M., POLITIEK, Klaziena, OLDHOFF, Marja, DE GRAAF, Marlies, SCHUTTELAAR, Marie L. A., and DE BRUIN-WELLER, Marjolein S.
- Subjects
- *
ATOPIC dermatitis , *BARICITINIB , *HERPES simplex , *URINARY tract infections , *KINASE inhibitors , *DUPILUMAB - Abstract
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-weeks' treatment with baricitinib in adult patients with moderate-to-severe atopic dermatitis in daily practice. A total of 51 patients from the BioDay registry treated with baricitinib were included and evaluated at baseline and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed using clinician- and patient-reported outcome measurements. Adverse events and laboratory assessments were evaluated at every visit. At week 16, the probability (95% confidence interval) of achieving Eczema Area and Severity Index ≤ 7 and numerical rating scale pruritus ≤ 4 was 29.4% (13.1-53.5) and 20.5% (8.8-40.9), respectively. No significant difference in effectiveness was found between dupilumab non-responders and responders. Twenty-two (43.2%) patients discontinued baricitinib treatment due to ineffectiveness, adverse events or both (31.4%, 9.8% and 2.0%, respectively). Most frequently reported adverse events were nausea (n = 6, 11.8%), urinary tract infection (n = 5, 9.8%) and herpes simplex infection (n = 4, 7.8%). In conclusion, baricitinib can be an effective treatment option for moderate-to-severe atopic dermatitis, including patients with non-responsiveness on dupilumab. However, effectiveness of baricitinib is heterogeneous, which is reflected by the high discontinuation rate in this difficult-to-treat cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Altered Maturation of the Skin Microbiome in Infants with Atopic Dermatitis.
- Author
-
OLESEN, Caroline M., CLAUSEN, Maja-Lisa, AGNER, Tove, ASPLUND, Maria, RASMUSSEN, Linett, YÜKSEL, Yasemine T., ANDERSEN, Paal S., LITMAN, Thomas, HANSEN, Anders J., and BARNES, Christopher J.
- Subjects
- *
ATOPIC dermatitis , *INFANTS , *COMMUNITIES - Abstract
The aim of this study was to investigate the early-life development of the skin microbiome in atopic dermatitis. Nineteen infants with atopic dermatitis and 19 healthy infants were evaluated 3 times, at 3 months intervals, within the first 30 months of life. Tape-strips were collected from volar forearms, cheeks, and eczema lesions, and the skin microbiome was assessed by 16S rRNA sequencing. Both the community structure and richness of the skin microbiome of infants with atopic dermatitis differed significantly from that of healthy infants, with greater richness in healthy infants. For infants with atopic dermatitis, the community composition was not dominated by Staphylococci. For healthy infants, community composition and richness correlated significantly with age, while such a pattern was not revealed in infants with atopic dermatitis. This suggests a slower maturation of the skin microbiome in atopic dermatitis, which precedes the staphylococcal predominance observed in older children and adults. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey.
- Author
-
AUGUSTIN, Matthias, COSTANZO, Antonio, PINK, Andrew, SENESCHAL, Julien, SCHUSTER, Christopher, MERT, Can, GUERREIRO, Mariana, TIETZ, Nicole, GROND, Susanne, and DE BRUIN-WELLER, Marjolein
- Subjects
- *
ATOPIC dermatitis , *PATIENT satisfaction , *BODY surface area , *DISEASE management , *THERAPEUTICS - Abstract
Atopic dermatitis is a chronic inflammatory skin disorder associated with a heterogeneous presentation and considerable disease burden. Exploring atopic dermatitis treatment patterns and patient benefits could improve disease management and patients' quality of life. This study aimed to describe current and previous atopic dermatitis treatment patterns and patient benefits from those treatments to inform disease management. Data were collected in 10 countries. Adults (n = 1,988) with confirmed moderate-to-severe atopic dermatitis completed a web-based cross-sectional survey. Most patients (86.6%) had body surface area involvement <10%, and therapies used were topical (69.7%), systemic (28.1%), and biologics (2.3%). Most flares were managed by topical monotherapies (73.4%), even in patients with body surface area involvement ≥10%. Treatment expectations were met only partially, or not at all, in 75% of patients. Those with body surface area involvement ≥10% reported lower treatment satisfaction. Overall, this study highlights the unmet medical needs in atopic dermatitis management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
- Author
-
SEDEH, Farnam B., HENNING, Mattias A. S., JEMEC, Gregor B. E., and IBLER, Kristina S.
- Subjects
- *
ATOPIC dermatitis , *MONOCLONAL antibodies , *KINASE inhibitors , *DUPILUMAB , *RANDOMIZED controlled trials - Abstract
The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All randomized controlled trials investigating the efficacy of systemic treatments for moderate-to-severe atopic dermatitis in adults were included. Primary outcomes were the proportion of patients with atopic dermatitis achieving 50%, 75%, and 90% improvement in Eczema Area and Severity Index (EASI) score after dupilumab, tralokinumab or Janus kinase inhibitors. Nineteen studies totalling 6,444 patients were included. In monotherapy studies, upadacitinib 30 mg once daily had the numerically highest efficacy regarding EASI-50, EASI-75 and EASI-90. In combination therapy studies with topical corticosteroids, dupilumab 300 mg once every other week had highest efficacy regarding EASI-50, and abrocitinib 200 mg once daily had the highest score regarding EASI-75 and EASI-90. Analysis provided evidence that dupilumab, tralokinumab and Janus kinase inhibitors all had an acceptable efficacy profile and resulted in clinically relevant improvements in EASI score. Furthermore, upadacitinib and abrocitinib seem to have great potential to treat patients with atopic dermatitis. However, further studies are needed to determine the long-term efficacy of Janus kinase inhibitors in adults with moderate-to-severe atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. The Atopic Dermatitis Control Tool: A High-Performance Tool for Optimal Support.
- Author
-
STAUMONT-SALLÉ, Delphine, TAIEB, Charles, MERHAND, Stephanie, and SHOURICK, Jason
- Subjects
- *
ATOPIC dermatitis , *PREVENTIVE medicine , *WOMEN patients , *CROSS-sectional method - Abstract
The evaluation of global atopic dermatitis control is key to minimizing disease burden. The Atopic Dermatitis Control Tool (ADCT) has been developed for this purpose. Participants (diagnosed by a physician) were recruited to this observational cross-sectional study using real-life methodology and completed a questionnaire on sociodemographic and personal information. The ADCT algorithm, described by Pariser, was used to categorize patients as having controlled or uncontrolled atopic dermatitis. Data were collected for 1,606 patients. Median age of the patients was 40 years, and 1,023 (63.7%) patients were women. A total of 1,146 (71.4%) patients had uncontrolled atopic dermatitis according to the ADCT score. Patients with uncontrolled disease were at significantly higher risk of a high stress level and were more likely to be absent from work than those with controlled disease. In conclusion, a key factor for predicting disease burden in atopic dermatitis is patient self-assessed disease control in terms of multiple dimensions: stress, sleep, quality of life, work absenteeism and loss of productivity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Factors Associated with Affective Symptoms and Quality of Life in Patients with Atopic Dermatitis.
- Author
-
FERRUCCI, Silvia Mariel, TAVECCHIO, Simona, ANGILERI, Luisa, SURACE, Teresa, BERTI, Emilio, and BUOLI, Massimiliano
- Subjects
- *
ATOPIC dermatitis , *AFFECT (Psychology) , *ONE-way analysis of variance , *QUALITY of life , *MENTAL depression , *ITCHING , *ECZEMA - Abstract
The aim of this study was to detect demographic and clinical factors associated with affective symptoms and quality of life in patients with severe atopic dermatitis. First, one-way analyses of variance and correlations were performed to compare a large set of qualitative and quantitative clinical variables. Three final multivariable regression models were performed, with depression/anxiety subscales and Dermatology Life Quality Index scores as dependent variables, and the factors that were statistically significant on univariate analyses as independent ones. More severe anxiety symptoms and poorer quality of life (p < 0.01) were significantly associated with more severe depressive symptoms. Female sex and disturbed sleep (p = 0.03) were significantly associated with more severe anxiety. Finally, previous treatment with cyclosporine (p = 0.03) or methotrexate (p = 0.04), more severe depressive symptoms (p < 0.01), itch (p = 0.03), impaired sleep (p < 0.01) and perceived severity of dermatological illness (p < 0.01) were significant predictors of low quality of life. This study shows a complex interplay between the severity of atopic dermatitis, poor quality of life and presence of clinically relevant affective symptoms. These results will help dermatologists to identify patients who need psychiatric consultation within the framework of a multidisciplinary approach. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. General Burden of Adult Atopic Dermatitis: An Observational Study of Disease Perceptions among Patients and Dermatologists in France.
- Author
-
SORIA, Angèle, THÉNIÉ, Claire, BIENENFELD, Christina, and STAUMONT-SALLÉ, Delphine
- Subjects
- *
ATOPIC dermatitis , *PATIENTS' attitudes , *DERMATOLOGISTS , *ADULTS , *SCIENTIFIC observation - Abstract
It is important to understand patients' and dermatologists' perceptions of various aspects of atopic dermatitis, but there is a lack of studies on quality of life and stakeholder viewpoints in this therapy area. The aim of this study was to compare patients' and dermatologists' viewpoints regarding the impact of atopic dermatitis that is uncontrolled by topical corticosteroids. Data were collected from 348 adult patients who responded to self-administered questionnaires, and 150 telephone interviews with the dermatologists who selected them. Patients and dermatologists reported both convergent and divergent assessments of the impact of atopic dermatitis and its treatment. Notable areas of agreement were regarding the safety of emollients, the time required and difficulty of applying topical corticosteroids, especially to certain parts of the body. Divergent views involved the perceived efficacy of available treatments and the impact of atopic dermatitis on professional life. A greater understanding of these differences would help dermatologists to optimize patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.